BioSpace8h
Boehringer Ingelheim’s Lung Fibrosis Drug Scores Second Late-Stage Win
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
BioSpace10h
AbbVie Gets FDA Approval for New Antibiotic in the Face of Rising Resistance
The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...
BioSpace10h
BMS Positions Breyanzi for Another Indication as LOE Woes Mount
Adding a new indication for the CAR T cell therapy could help BMS offset the loss-of-exclusivity headwinds it faces in the ...
BioSpace11h
Bain Bets Big on Japanese Market With $3.3B Tanabe Buy
The carve-out acquisition will allow Bain to capitalize on the “promising signs for growth” in the Japanese life sciences ...
BioSpace12h
Pliant Stock Crashes After Suspension of Idiopathic Pulmonary Fibrosis Study
It is unclear why an independent data safety monitoring board recommended the suspension of Pliant’s Phase IIb/III BEACON-IPF ...
BioSpace12h
AceLink’s Fabry Hopeful Shows Potential in Mid-Stage Study
AceLink is advancing a small-molecule treatment option for Fabry disease, which could provide a more convenient alternative ...